Therapeutics clinic

New medications for diabetes: when to use what?

Therapeutics clinic

New medications for diabetes: when to use what?

Lisa M. Raven, Roger Chen

Figures

© FATCAMERA/ISTOCKPHOTO.COM models used for illustrative purposes only
© FATCAMERA/ISTOCKPHOTO.COM models used for illustrative purposes only

Abstract

The prevalence of type 2 diabetes mellitus continues to increase and, with newer medications available, it is important to tailor therapy to the individual.  We have learnt from the cardiovascular outcome trials that there are now diabetes medications that can potentially modulate cardiac and renal outcomes irrespective of their glycaemic effects.

Article Extract

The focus of this article is to explore the use of newer diabetes medications: sodium-glucose cotransporter-2 (SGLT-2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl-peptidase-4 (DPP-4) inhibitors. Lifestyle optimisation with adequate exercise and healthy food choices remains a mainstay of management of diabetes and should be discussed at each appointment. Intensive weight management intervention has been shown to be effective and, in some cases, can lead to diabetes remission.1,2 Guidelines for the management of type 2 diabetes by Diabetes Australia and the Royal Australian College of General Practitioners are available online.3,4 This article contains general discussion about the TGA and PBS approvals; however, more information can be found at their respective websites.5,6